Free Trial
NASDAQ:EDSA

Edesa Biotech 5/14/2025 Earnings Report

Edesa Biotech logo
$1.96 +0.01 (+0.51%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$1.96 +0.01 (+0.26%)
As of 06/5/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.30
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edesa Biotech Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Edesa Biotech's next earnings date is estimated for Friday, August 8, 2025, based on past reporting schedules.

Conference Call Resources

Edesa Biotech Earnings Headlines

The Age of Chaos has begun
This is one of the most confusing markets in history. We have entered an Age of Chaos. And you must take six steps immediately to protect yourself, whether the market is falling or not.
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

View Edesa Biotech Profile

More Earnings Resources from MarketBeat